Salloum Fadi N, Tocchetti Carlo G, Ameri Pietro, Ardehali Hossein, Asnani Aarti, de Boer Rudolf A, Burridge Paul, Cabrera José-Ángel, de Castro Javier, Córdoba Raúl, Costa Ambra, Dent Susan, Engelbertsen Daniel, Fernández-Velasco María, Fradley Mike, Fuster José J, Galán-Arriola Carlos, García-Lunar Inés, Ghigo Alessandra, González-Neira Anna, Hirsch Emilio, Ibáñez Borja, Kitsis Richard N, Konety Suma, Lyon Alexander R, Martin Pilar, Mauro Adolfo G, Mazo Vega Manuel M, Meijers Wouter C, Neilan Tomas G, Rassaf Tienush, Ricke-Hoch Melanie, Sepulveda Pilar, Thavendiranathan Paaladinesh, van der Meer Peter, Fuster Valentin, Ky Bonnie, López-Fernández Teresa
Pauley Heart Center, Division of Cardiology, Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA.
Department of Translational Medical Sciences, Center for Basic and Clinical Immunology Research, Interdepartmental Center of Clinical and Translational Sciences, Interdepartmental Hypertension Research Center, Federico II University, Naples, Italy.
JACC CardioOncol. 2023 Sep 27;5(6):715-731. doi: 10.1016/j.jaccao.2023.08.003. eCollection 2023 Dec.
Despite improvements in cancer survival, cancer therapy-related cardiovascular toxicity has risen to become a prominent clinical challenge. This has led to the growth of the burgeoning field of cardio-oncology, which aims to advance the cardiovascular health of cancer patients and survivors, through actionable and translatable science. In these Global Cardio-Oncology Symposium 2023 scientific symposium proceedings, we present a focused review on the mechanisms that contribute to common cardiovascular toxicities discussed at this meeting, the ongoing international collaborative efforts to improve patient outcomes, and the bidirectional challenges of translating basic research to clinical care. We acknowledge that there are many additional therapies that are of significance but were not topics of discussion at this symposium. We hope that through this symposium-based review we can highlight the knowledge gaps and clinical priorities to inform the design of future studies that aim to prevent and mitigate cardiovascular disease in cancer patients and survivors.
尽管癌症生存率有所提高，但癌症治疗相关的心血管毒性已上升成为一个突出的临床挑战。这促使了新兴的心脏肿瘤学领域的发展，该领域旨在通过可行且可转化的科学来促进癌症患者及幸存者的心血管健康。在这些2023年全球心脏肿瘤学研讨会科学会议论文集中，我们重点回顾了本次会议讨论的导致常见心血管毒性的机制、为改善患者预后而正在进行的国际合作努力，以及将基础研究转化为临床护理的双向挑战。我们认识到还有许多其他重要疗法，但并非本次研讨会的讨论主题。我们希望通过基于本次研讨会的综述，能够突出知识空白和临床重点，为未来旨在预防和减轻癌症患者及幸存者心血管疾病的研究设计提供参考。
